Techne, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $297.03 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.11%.
MINNEAPOLIS (AP) — MINNEAPOLIS (AP) — Techne Corp. (TECH) on Wednesday reported fiscal second-quarter earnings of $34.9 million. On a per-share basis, the Minneapolis-based company said it had ...
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...
Bio-Techne (TECH) announced the launch of an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation ...
Feb 5 (Reuters) - Bio-Techne (TECH.O), opens new tab beat second-quarter profit and revenue estimates on Wednesday, helped by growth in its protein sciences unit that makes products to develop ...
TECHNE is a practice-based digital arts research initiative founded by Professor Mark Amerika, at the University of Colorado at Boulder. The TECHNE initiative develops innovative approaches to the ...
Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets.
Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral ...
Bio-Techne during Q4, while other hedge funds adjusted their holdings.,Many market reports reflect an optimistic view of ...
Shares of Bio-Techne Corporation (NASDAQ:TECH) traded higher after the life sciences company topped analysts' expectations with its Q2 FY25 results, indicating a faster topline growth amid early ...
Headquartered in Minneapolis, Minnesota, Bio-Techne Corporation (TECH) is a leading provider of life sciences solutions dedicated to advancing biomedical research and diagnostics. With a market ...
Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in Bio-Techne by 1.8% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 16,347 shares of the ...